Testing IBD0333 for advanced solid tumors or lymphoma
Part of Cancer clinical trials.
This trial tests an experimental drug called IBD0333 for people with advanced solid tumors or lymphoma who have run out of standard options. The drug targets a protein called 4-1BB to help your immune system fight cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have advanced cancer (solid tumor or lymphoma) that has not responded to standard treatments, or you cannot tolerate those treatments.
- You are able to walk and do light work (ECOG score 0 or 1).
- Your blood counts, liver, and kidney function are within certain safe ranges.
- You have not had certain cancer treatments recently (like chemotherapy, radiation, or immunotherapy) within the past few weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called IBI3005 for people whose solid tumors (cancers that form lumps) have continued to grow despite treatment with a specific targeted therapy (EGFR TKI). The goal is to see if IBI3005 can help when other treatments have stopped working.
This trial tests a combination of two experimental drugs (LB1410 and LB4330) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments or where no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.
This study tests a new drug called IBI3026 for people with advanced solid tumors that cannot be surgically removed or have spread. The goal is to see if it is safe and helps control the cancer.
This early-stage trial tests a new drug called IBI3028 in people with advanced cancers that cannot be removed by surgery or have spread. The study aims to find the right dose and understand how the drug works in your body.
This trial tests a new drug called IBI3001 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective against different types of cancer.
This study tests a new drug, ILB-3101, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and how well it works.
Hear when a new MTD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.